Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study

Simple item page
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorTimotheadou, H.en
dc.contributor.authorRammou, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:32:46Z
dc.date.available2015-11-24T19:32:46Z
dc.identifier.issn0959-4973-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23452
dc.rightsDefault Licence-
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectCamptothecin/administration & dosage/adverse effects/*analogs &en
dc.subjectderivatives/*therapeutic useen
dc.subjectClinical Trials, Phase II as Topicen
dc.subjectDiarrhea/chemically induceden
dc.subjectDose-Response Relationship, Drugen
dc.subject*Drug Administration Scheduleen
dc.subjectFemaleen
dc.subjectGreeceen
dc.subjectHematologic Diseases/chemically induceden
dc.subjectHumansen
dc.subjectInfusions, Intravenous/*methodsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPatient Selectionen
dc.subjectTaxoids/administration & dosage/adverse effects/*therapeutic useen
dc.subjectTime Factorsen
dc.subjectTreatment Outcomeen
dc.subjectWithholding Treatment/ethicsen
dc.titleBiweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I studyen
heal.abstractWe developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine the toxicity spectrum, and define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended optimal dose (ROD) of irinotecan infused over 24 h and followed by a 1-h infusion of 30 mg/m2 docetaxel. Starting dose for irinotecan was 30 mg/m2 and escalation proceeded at 30 mg/m2 increments, in cohorts of three to six patients until the MTD was reached. A dose between the MTD and the previous level was explored to further define the ROD. Thirty-two patients with advanced refractory cancers (median age 64, 19 male) received 190 treatment courses at five dosing levels of irinotecan: 30 mg/m2 (n=6 patients), 60 (n=3), 90 (n=7), 120 (n=8) and 105 (n=8). The MTD and ROD was 120/30 and 105/30 mg/m2. DLTs were diarrhea and neutropenia. Antitumor activity was modest. The ROD of biweekly administration of 24-h irinotecan followed by 1-h docetaxel is 105 and 30 mg/m2, respectively. The low hematological toxicity and modest activity observed leave questions concerning the optimal timing of this combination.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15494635-
heal.journalNameAnticancer Drugsen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2004-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ